Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Type 1 Diabetes Intervention With Mazdutide for Efficacy, Safety and Cardiovascular Protection (The TIMES Trial Program-TIMES-EFFICACY & TIMES-CV

NCT07924553 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07924553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Type 1 Diabetes Intervention With Mazdutide for Efficacy, Safety and Cardiovascular Protection (The TIMES Trial Program-TIMES-EFFICACY & TIMES-CV
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
June 1, 2029
Enrollment
182 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes

Arms

As registered; 2 arms.

  • mazdutide group ExperimentalMazdutide

    Participants in the treatment group will receive mazdutide by subcutaneous injection once weekly. The dose will be escalated stepwise according to a pre-defined regimen from a safe starting dose to an effective maintenance dose (from 2 mg to 4 mg) over several weeks, with dose reduction permitted if needed.

  • placebo group Placebo comparatorPlacbo

    Participants in the control group will receive a placebo matched to mazdutide in appearance, packaging, and mode of administration, by subcutaneous injection once weekly.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Proportion of the participants achieving time in range (TIR)>70 and time below range (TBR)<4% (TIMES-EFFICACY) From baseline to 16 weeks

    The proportion of adult patients with T1D achieving the composite outcome of continuous glucose monitoring (CGM)-measured TIR \>70% and TBR \<4% at Week 16 in the mazdutide group versus the placebo group

  • Volume of non-calcified coronary artery plaque (TIMES-CV) From baseline to 52 weeks

    The absolute change in non-calcified coronary artery plaque volume in mm³ from baseline to Week 52, as measured by quantitative analysis of high-resolution coronary computed tomography angiography (CCTA)

Lead sponsor's other trials

Peking University People's Hospital, most recent start first.

Similar trials

Same condition (Diabetes Mellitus, Type 1) and phase, most recent start first.